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Abstract
Introduction The phenotypic and functional differences
between cells that initiate human breast tumors (cancer stem
cells) and those that comprise the tumor bulk are difficult to
study using only primary tumor tissue. We embarked on this
study hypothesizing that breast cancer cell lines would contain
analogous hierarchical differentiation programs to those found
in primary breast tumors.
Methods Eight human breast cell lines (human mammary
epithelial cells, and MCF10A, MCF7, SUM149, SUM159,
SUM1315 and MDA.MB.231 cells) were analyzed using flow
cytometry for CD44, CD24, and epithelial-specific antigen
(ESA) expression. Limiting dilution orthotopic injections were
used to evaluate tumor initiation, while serial colony-forming unit,
reconstitution and tumorsphere assays were performed to
assess self-renewal and differentiation. Pulse-chase
bromodeoxyuridine (5-bromo-2-deoxyuridine [BrdU]) labeling
was used to examine cell cycle and label-retention of cancer
stem cells. Cells were treated with paclitaxol and 5-fluorouracil
to test selective resistance to chemotherapy, and gene
expression profile after chemotherapy were examined.
Results The percentage of CD44+/CD24- cells within cell lines
does not correlate with tumorigenicity, but as few as 100 cells
can form tumors when sorted for CD44+/CD24-/low/ESA+.
Furthermore, CD44+/CD24-/ESA+  cells can self-renew,
reconstitute the parental cell line, retain BrdU label, and
preferentially survive chemotherapy.
Conclusion These data validate the use of cancer cell lines as
models for the development and testing of novel therapeutics
aimed at eradicating cancer stem cells.
Introduction
The process of wound healing to replace damaged tissue
involves epithelial tissue regeneration; a small population of
replenishing stem cells gives rise to differentiated progeny that
replace the damaged tissue. This characteristic of accelerated
epithelial tissue regeneration is shared by the epithelial com-
ponent in a growing tumor, albeit on a genetically unstable
background. In fact, epithelial tumors have been described as
'wounds that do not heal' because of the molecular and cellu-
lar similarities between the mesenchyme associated with
wounds and that of carcinomas [1]. Many solid tumor types,
including breast cancer, exhibit a functional hierarchy of can-
cer cells of which only a small subpopulation of replenishing
stem-like cells can give rise to the differentiated cells that com-
prise the bulk tumor [2-6]. In human breast cancers, these
tumorigenic breast cancer stem cells are enriched in cells with
a CD44+/CD24-/low/ESA+ phenotype [2].
Other than the ability to seed a tumor in a nonobese diabetic
(NOD)/severe combined immunodeficient (SCID) mouse, it is
unclear what phenotypic and functional differences distin-
guish the cells that fuel carcinoma growth from cells that
BrdU = 5-bromo-2-deoxyuridine; CFU = colony-forming unit; DMSO = dimethyl sulfoxide; ESA = epithelial-specific antigen; 5-FU = 5-fluorouracil; 
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comprise the tumor bulk. Furthermore, it is unclear what mech-
anisms control the maintenance and survival of these tumori-
genic cells. These issues have been difficult to study, in part
because of the presupposed lack of appropriate model sys-
tems. Use of primary breast cancer cells is considered to be
the best means to study tumor repopulation because it is pre-
sumed that, upon long-term cultivation in vitro, cancer cells
lose the dynamic characteristics of a regenerating tissue [7].
However, experiments with primary tumor cells are costly and
difficult to control because of small sample size and the heter-
ogeneous nature of the cellular, genetic, and epigenetic com-
position among patient tissue samples.
In order to overcome problems associated with procuring and
using primary human tissues, continuous breast cancer cell
lines have been developed from various sources, including
pleural effusions (MDA.MB.231 and MCF7), primary breast
cancers (SUM149 and SUM159), primary tumor recurrences
(SUM225), and even xenografted metastatic nodules
(SUM1315) [8,9]. These cell lines represent polyclonal popu-
lations of cells that have adapted to tissue culture conditions
but retain many of their phenotypic and genotypic properties
over countless passages [9,10]. Genomic approaches have
revealed that, like primary tumors, the gene expression signa-
tures of breast cancer cell lines can distinguish luminal from
basal subtypes of breast cancer [11-13]. Moreover, cell line
derived gene signatures can correctly classify human tumor
samples [8,14]; this suggests that, despite their acquired abil-
ity to grow in vitro, cell lines continue to share many of the
molecular and genetic features of the primary breast cancers
from which they were derived.
Breast cancer cell lines will form tumors in immunodeficient
mice that recapitulate the histology, progression, and meta-
static spread of the disease [15-17]. Therefore, we postulated
that cancer cell lines may also retain the cellular hierarchy
characteristic of primary breast tumors. In this study, we report
that breast cancer cell lines contain a small population of cells
that mimic cancer stem cell behaviors. Similar to primary
breast cancers, cell line derived tumor-initiating cells are
enriched in cells with the CD44+/CD24-/low/epithelial-specific
antigen (ESA)+ phenotype. This work validates the use of cell
lines to elucidate the unique mechanisms that govern mainte-
nance and survival of tumorigenic breast cancer stem cells.
Materials and methods
Cell lines and tissue culture
SUM cell lines were obtained from Dr Stephen Ethier (Kra-
manos Institute, MI, USA) and are commercially available
(Asterand, Detroit, MI); the MDA.MB.231, MCF7, and
MCF10A cell lines were purchased from American Type Cul-
ture Collection (Manassas, VA, USA). Human mammary epi-
thelial cells immortalized with the catalytic subunit of
telomerase [18] were cultured in Dulbecco's modified Eagle's
medium-F12 (1:1) with 5% calf serum (Hyclone, Logan, UT),
insulin (5 μg/ml), hydrocortisone (1 μg/ml), and epidermal
growth factor (10 ng/ml; Sigma, St. Louis, MO). MCF10A and
MCF7 cells were cultured in Dulbecco's modified Eagle's
medium with 10% calf serum. MDA.MB.231 cells were cul-
tured in RPMI 1640 with 10% calf serum. SUM225CWR,
SUM149PT, and SUM159PT cells were cultured in Ham's
F12 with 5% calf serum, insulin (5 μg/ml), and hydrocortisone
(1 μg/ml), whereas SUM1315MO2 were in Ham's F12 with
5% calf serum, insulin (5 μg/ml), and epidermal growth factor
(10 ng/ml). All cell lines were grown at 37°C and 5% carbon
dioxide.
Flow cytometry
Nonconfluent cultures were trypsinized into single cell suspen-
sion, counted, washed with phosphate-buffered saline (PBS),
and stained with antibodies specific for human cell surface
markers: ESA-FITC (Biomeda), CD24-PE, and CD44-APC
(BD Pharmingen, San Jose, CA). A total of 250,000 cells were
incubated with antibodies for 15 minutes at room temperature.
Unbound antibody was washed off and cells were analyzed no
longer than 1 hr post staining on a BD Facscalibur.
Animals and surgery
All animal procedures were performed in accordance with an
approved protocol by the Tufts University Institutional Animal
Care and Use Committee. A colony of NOD/SCID mice was
maintained under sterile conditions and received food and
water ad libum. Nulliparous female mice aged 8 to 14 weeks
were utilized in all experiments. Human breast cancer cells
were resuspended in 1:1 (vol/vol) media and Matrigel (BD Bio-
sciences, San Jose, CA), and injected into the fourth inguinal
mammary gland. Tumor formation was assessed by palpitation
at least once a week.
Tumorsphere assays
A total of 5,600 single cells/cm2 were plated on super-low
adherence plates (Corning, Lowell, MA). Every 3 days, after
cells pelleting and resuspending in fresh media, spheres visi-
ble by eye (no magnification) were counted. Pictures were
taken to assess the ratio of spheres to aggregates of cells. To
correct for differing growth rates of the cell lines, the average
tumorsphere number on day 12 was divided by a proliferation
constant for the cell line. To quantify proliferation, cells were
seeded on day 0 at 50,000 cells/well in a six-well dish in dupli-
cate. Cells were fixed and stained with 0.1% crystal violet and
quantified by extraction in 10% acetic acid and spectropho-
tometer reading at optical density 600 nm. Spheres were frac-
tionated by size using 100 μm cell strainers (BD Pharmingen)
and trypsinized into single cell suspension for flow cytometric
analysis, as described above.
BrdU label retention
Nonconfluent cultures were pulsed with 10 μmol/l bromode-
oxyuridine (5-bromo-2-deoxyuridine [BrdU]) for 10 days, being
split and re-fed so that a total of 50 μmol/l BrdU was given toAvailable online http://breast-cancer-research.com/content/10/2/R25
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no more than 5 × 106 cells. Chased cells were analyzed at day
0, 4, 6, and 8 days for BrdU label retention. For these pulse-
chase studies, at day 0 totals of 10,000, 5,000, or 1,000
BrdU-labeled cells were added per well of a four-well chamber
slide and fixed at 4, 6, or 8 days after chase, respectively. Cells
chased with chemotherapy were analyzed at day 6. For
immunofluorescence, cells were prepared similarly to those
described in Shinin and coworkers (2006) using 4% parafor-
maldehyde and 0.1% saponin in PBS as a fixative; 0.25% Tri-
ton-X and 0.1% bovine serum albumin in PBS as a
permeabilization buffer; and 0.02 U/μl of DNase (NE Biolabs,
Ipswich, MA). Antibodies used were mouse monoclonal anti-
BrdU (BD Pharmingen), rabbit polyclonal anti-Ki67 (Abcam,
Cambridge, MA), and anti-mouse Alexa 488 (Molecular
probes). Slides were mounted in Vecta-shield mounting media
with DAPI (4',6 diamidino-2-phenylindole; Vector Laborato-
ries, Burlingame, CA, USA). For flow cytometry, mouse mono-
clonal anti-EpCAM (Abcam), anti-mouse PerCP, and the
BrdU-FITC set of antibodies was used (BD Pharmingen).
Chemotherapy treatment
Confluent plates were split 1:4 and treated the following day
with a 1:100 dilution of 0.1 mol/l 5-fluorouracil (5-FU) in dime-
thyl sulfoxide (DMSO) for a final concentration of 1 mmol/l 5-
FU, or 1 μm paclitaxel in DMSO for a final concentration of 10
nmol/l Taxol (Sigma). Placebo control plates received 1:100
DMSO. Cells were fed and re-treated at 3 days and analyzed
at 6 days.
Results
Percentage of CD44+/CD24- cells associates with a basal 
phenotype, not tumorigenicity
Breast cancers are broadly categorized into two classes:
those that express luminal keratins (luminal-type) and those
that express stratified epithelial keratins (basal-type)
[11,12,19,20]. Recent work has characterized the cellular het-
erogeneity of human breast tissues based on cell surface
expression of CD44 and CD24, using epithelial cells from pri-
mary reduction mammoplasty tissues, pleural effusions, and
primary tumors [21]. CD44+/CD24- cells exhibit features of
basal cells and express genes that are involved in motility,
whereas CD24+/CD44- cells exhibit features of more differen-
tiated luminal epithelial cells and express genes involved in
hormone responses.
To examine whether breast cancer cell lines adhere to a similar
molecular definition, we examined eight different human breast
cell lines with differing tumorigenic, invasive, and metastatic
potentials (Additional file 1). Using flow cytometry, cell lines
could be could be grouped into three classes based on CD44
and CD24 expression profiles (Figure 1a and Additional file 2).
Class 1 (luminal) includes the MCF7 and SUM225 lines that
were mainly CD24+ and exhibit a more differentiated morphol-
ogy and luminal cytokeratin expression, which is consistent
with their luminal-type classification (Figure 1a; data not
shown) [8,21]. Class 2 (basal/mesenchymal) consists of the
MDA.MB.231, SUM159, and SUM1315 lines that are more
than 90% CD44+/CD24-  cells and exhibit a spindle-like
appearance, consistent with their basal-type classification.
Finally, Class 3 (mixed) consists of the SUM149 and human
mammary epithelial cell lines, both of which exhibit two distinct
CD44/CD24 populations and contain distinct populations of
cells with either basal-like or luminal-like features. These data
suggest that cultured breast cell lines maintain a similar cellu-
lar definition as cells in primary human tissues.
Cells from primary human breast tumors with a CD44+/CD24-
/low phenotype enrich for tumor formation in vivo [2]. Because
basal cell lines comprise more than 90% CD44+/CD24- cells,
we reasoned these lines should be more tumorigenic than the
mixed cell line, SUM149, which contains an average of 18-fold
fewer CD44+/CD24- cells (Figure 1b). To compare quantita-
tively the tumorigenicity of the cell lines, we performed limiting
dilution injection experiments. SUM149, SUM1315, and
SUM159 cell lines were injected into NOD/SCID mice in a 10-
fold dilution series from 1 × 106 to 1 × 103 cells per mammary
gland and the mice were monitored for tumor growth (Figure
1c). Despite containing more than 90% CD44+/CD24- cells,
the SUM1315 and SUM159 lines form tumors only 50% or
60% of the time with 10,000 cells injected, respectively. Sur-
prisingly, SUM149 line, which contains only about 5%
CD44+/CD24- cells, exhibits a tumorigenic potential similar to
that of the SUM159 and SUM1315 lines. Collectively, these
data suggest that, analogous to primary breast cancers [21],
a basal cellular phenotype rather than tumorigenicity consist-
ently correlates with the percentage of CD44+/CD24- cells in
cell lines.
Breast cancer cell lines contain CD44+/CD24-/ESA+ 
breast cancer stem-like cells
Because the percentage of CD44+/CD24- cells in breast can-
cer cell lines does not predict tumorigenic potential, we next
considered whether adding ESA to the repertoire of cell sur-
face markers could enrich for tumor initiation capacity, as was
previously demonstrated [2]. ESA and CD24 are coexpressed
in malignant breast cell lines, such that ESA expression can
substitute for CD24 expression in classifying the lines into
luminal, basal, and mixed phenotypes (Figure 2a–c). The lumi-
nal lines, MCF7 and SUM225, exhibit two populations of ESA-
expressing cells; the majority express high levels of ESA, as
indicated by immunofluorescence and flow cytometry (ESA+),
whereas a smaller subset of cells express a lower level
(ESAlow; Figure 2a). Conversely, the basal lines SUM159,
SUM1315, and MDA.MB.231 contain a large population of
ESA-negative (ESA-) cells and a smaller subset of cells
expressing low levels ESA (ESAlow; Figure 2b). Finally, mixed
cell lines such as SUM149, which contains both basal and
luminal cell types, exhibit three ESA populations: those that
are negative for ESA (ESA-) and two populations of ESA-pos-
itive cells, namely ESA+ and ESAlow cells (Figure 2c).Breast Cancer Research    Vol 10 No 2    Fillmore and Kuperwasser 
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Figure 1
CD44+/CD24- cells associate with a basal phenotype not with tumorigenic potential of human breast cancer cell lines CD44+/CD24- cells associate with a basal phenotype not with tumorigenic potential of human breast cancer cell lines. (a) Luminal, basal or mixed 
cell morphology can be predicted based on CD44 and CD24 expression. Provided are representative flow cytometry dot plots of CD44 and CD24 
expression adjacent to phase-contrast brightfield images of each cell line subtype. Cell lines are composed of luminal-like, CD24+ expressing cells 
(MCF7 and SUM225); basal-like, CD24- expressing cells (SUM159, SUM1315, and MDA.MB.231); or mixed luminal and basal-like cells and con-
sist of both CD24+ and CD24- populations (human mammary epithelial cells [HMEC] and SUM149). (b) The average percentage of CD44+/CD24- 
cells in each cell line was determined by flow cytometry. Data are presented as the mean ± standard error of the mean for four separate experiments. 
(c) The frequency of tumor growth was measured for SUM149, SUM159, and SUM1315 cell lines injected orthotopically in nonobese diabetic/
severe combined immunodeficient mice when a tumor was palpable (>3 mm) within 100 to 150 days.
Figure 2
ESA can distinguish luminal, basal, and stem-like cells ESA can distinguish luminal, basal, and stem-like cells. Presented are representative flow cytometry dot plots of epithelial-specific antigen (ESA) and 
CD24 expression adjacent to ESA immunofluorescence of each cell line subtype. Cell lines are as follows: (a) luminal-like, expressing high levels of 
ESA and CD24 (MCF7, SUM225, and T47D); (b) basal-like, expressing low levels of ESA and CD24 (SUM159, SUM1315, and MDA.MB.231); or 
(c) mixed luminal/basal cultures that contain both ESA+/CD24+ and ESA-/CD24- populations (SUM149). (d) The average percentage of CD44+/
CD24-/ESA+ cells in each cell line, as determined by flow cytometry. Data are presented as the mean ± stamdard error of the mean for five separate 
experiments. HMEC, human mammary epithelial cells.Available online http://breast-cancer-research.com/content/10/2/R25
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Using flow cytometry, CD44+/CD24-/ESA+  cells were
detected in all of the lines examined (Figure 2d). The percent-
age of CD44+/CD24-/ESA+ cells ranges from 0.01% to 0.5%
in luminal lines, such as MCF7 and SUM225, to about 2.5%
in the basal and mixed cell lines SUM149, SUM159,
SUM1315, and MDA.MB.231 (Figure 2d). Most importantly,
there is a clear correlation (P < 0.0001) between the percent-
age of CD44+/CD24-/ESA+ cells in a cell line and the tumori-
genic and aggressive phenotype of the line in vivo (Additional
file 1 and Figure 2d).
We hypothesized that CD44+/CD24-/low/ESA+  cells are
enriched for tumorigenic potential as compared with the bulk
of the cell line. Therefore, SUM159 and SUM1315 lines were
sorted for CD44+/CD24-/low/ESA+ and CD44+/CD24-/ESA-
cells (Figure 3a), whereas the SUM149 cell line was sorted for
CD44+/CD24-/low/ESA+ and CD44+/CD24+/ESA+ cells (Fig-
ure 3b); all sorted fractions were injected into NOD/SCID
mice as a 10-fold dilution series from 1 × 106 to 1 × 102 cells
per mammary gland.
With as few as 100 cells, CD44+/CD24-/low/ESA+ subpopula-
tions from SUM159 and SUM149 cell lines could form tumors
in NOD/SCID mice, whereas unsorted, CD44+/CD24-/ESA-,
or CD44+/CD24+/ESA+ fractions were unable to do so at the
same dilution (Table 1). Similar results were seen with 1,000
cells injected for the SUM1315 line. Histological examination
of tissue sections reveals that unsorted SUM159 cells form
highly invasive spindle-cell carcinomas, and this spindle-cell
morphology is recapitulated in SUM159 tumors derived from
1 × 103 CD44+/CD24-/low/ESA+ cells (Figure 3c). Tumors
could from with as many as 1 × 106 SUM159 CD44+/CD24-/
ESA- cells, but these tumors lacked the morphology of the
parentally derived tumors in all sections investigated (Figure
3c). The tumor histology of unsorted SUM149 cells resembles
high-grade carcinomas that incorporate mouse stroma (Figure
Figure 3
CD44+/CD24-/low/ESA+ cells in human breast cancer cell lines enrich for tumorigenicity CD44+/CD24-/low/ESA+ cells in human breast cancer cell lines enrich for tumorigenicity. Shown are representative flow cytometry analysis and gates 
for epithelial-specific antigen (ESA), CD24 and CD44 sorting. (a) SUM159 cells were sorted on ESA. Dot plots show resulting CD44+/CD24-/low/
ESA+ or CD44+/CD24-/ESA- fractions. (b) SUM149 cells were sorted on CD44 and CD24 and subsequently sorted for ESA+, shown in histo-
grams. (c) Histological analysis of SUM159 and SUM149 orthotopic tumors. The upper panels present representative hematoxylin and eosin 
stained sections at 20× magnification of tumors that formed from 5 × 105 unsorted, 1,000 CD44+/CD24-/low/ESA+, or 1 × 106 CD44+/CD24-/ESA- 
SUM159 cells. Note that the tumor histology from CD44+/CD24-/ESA- sorted cells is different than that from unsorted or CD44+/CD24-/low/ESA+ 
cells. The lower panels present hematoxylin and eosin stained sections at 20× magnification of tumors that formed from 1 × 105 unsorted, CD44+/
CD24-/low/ESA+, or CD44+/CD24+/ESA+ sorted SUM149 cells. Note the tumor histology from CD44+/CD24+/ESA+ sorted cells is markedly differ-
ent from that of the unsorted or the CD44+/CD24-/low/ESA+ sorted cells.Breast Cancer Research    Vol 10 No 2    Fillmore and Kuperwasser 
Page 6 of 13
(page number not for citation purposes)
3c). This morphology is only recapitulated in tumors derived
from the CD44+/CD24-/low/ESA+  sorted cells (Figure 3c).
Examination of the injection sites where CD44+/CD24+/ESA+
and CD44+/CD24-//ESA- cells were unable to form tumors
revealed viable cells and Matrigel at the site of injection (data
not shown), confirming that lack of tumor growth from these
cells was not due to clearing or cell death.
Although tumors will form if more than 100,000 CD44+/
CD24-/low/ESA- and CD44+/CD24+/ESA+ cells are injected,
only tumors from CD44+/CD24-/low/ESA+ cells, even with as
few as 100 cells, phenocopy parentally derived tumors. There-
fore, cells from the parental cell line that preferentially seed
tumors segregate with the CD44+/CD24-/low/ESA+ subpopu-
lation. Collectively, these data show that breast cancer cell
lines contain cells with the capacity to form large tumors from
few seeding cells. Moreover, these resulting tumors recapitu-
late the cellular heterogeneity of tumors derived from the
unsorted parental cell line. Hence, similar to the case in pri-
mary tumors, these tumorigenic breast cancer stem-like cells
are enriched 100-fold in the CD44+/CD24-/low/ESA+ fraction
across multiple cell lines. (Additional file 3).
CD44+/CD24-/ESA+ cells can self-renew and reconstitute 
the parental cell line
The ability to both self-renew and differentiate into heteroge-
neous cell types is the definition of a stem cell that is thought
to be functionally mimicked by cancer stem cells [7,22-25].
The only way to distinguish between highly proliferative pro-
genitors and stem cells is the ability of the latter to grow indef-
initely. However, because established cancer cell lines, by
definition, have the ability to grow indefinitely, serial in vivo
passaging may not necessarily accurately assess self-renewal
of stem-like cells. Because serial colony-forming unit (CFU)
assays have been used to assay stem cell self-renewal in other
systems [26], we examined whether sorted CD44+/CD24-/
ESA+ cells contain more serial CFUs than other subpopula-
tions. To this end, SUM159 and SUM149 cells were sorted
into CD44+/CD24-/ESA+, CD44+/CD24-/ESA-, and CD44+/
CD24+/ESA+ populations and seeded at low density. Six days
later, colonies larger than 30 cells were quantified in order to
determine which fraction of cells exhibits the greatest CFU
activity.
After initial seeding, all sorted phenotypes from the SUM159
line exhibit similar plating efficiency and colony formation,
although unsorted, CD44+/CD24-/ESA+, and CD44+/CD24-/
ESA- populations formed more colonies than did the CD44+/
CD24+/ESA+ cells (P < 0.0003; Figure 4a, blue bars). The
day 6 colonies were trypsinized and replated at the same low
density for two additional rounds in order to assay for self-
renewal and clonogenic potential of the cells that seeded the
initial colonies. After the second round of passaging, the
CD44+/CD24+/ESA+ sorted cells exhibit the most depleted
clonogenic potential among all the populations (P < 0.0001;
Figure 4a, red bars). Upon the third serial replating, unsorted
(P = 0.063) and CD44+/CD24-/ESA+ sorted (P = 0.001) cells
continue to enrich for CFUs, whereas the CD44+/CD24+/
ESA+ and CD44+/CD24-/ESA- sorted cells exhibit evidence of
exhaustion at the third passage (Figire 4a, yellow bars versus
red bars). Similar results were seen upon serially replating
sorted SUM149 cells (data not shown).
To assess the ability of the various populations to differentiate
and reconstitute the parental cell line, SUM159 and SUM149
cells were sorted on the basis of CD44, CD24 and ESA sub-
populations (Figure 4b), plated, and allowed to expand in vitro
for 12 days. Expanded cultures were then analyzed by flow
Table 1
Limiting dilution tumor formation of CD44+/CD24-/low/ESA+ sorted cells in vivo
Cell type Days Number injected and tumors formed
1 × 106 1 × 105 1 × 104 1 × 103 1 × 102
SUM159 unsorted 13–100 5/5 5/6 5/8 3/8 0/2
SUM159 CD44+/CD24-/ESA- 20–100 8/10 2/2 1/2 0/8 0/10
SUM159 CD44+/CD24-/low/ESA+ 20–100 - - 2/2 6/6 6/10
SUM1315 unsorted 20–150 2/2 2/2 2/4 0/4 -
SUM1315 CD44+/CD24-/ESA- 25–150 3/4 2/2 0/4 0/10 -
SUM1315 CD44+/CD24-/low/ESA+ 20–150 - - 3/4 7/8 -
SUM149 unsorted 19–150 4/4 3/4 2/4 1/4 0/2
SUM149 CD44+/CD24+/ESA+ 20–150 - 2/2 0/4 0/4 0/6
SUM149 CD44+/CD24-/low/ESA+ 48–150 - 2/2 2/4 6/6 5/6
ESA, epithelial-specific antigen.Available online http://breast-cancer-research.com/content/10/2/R25
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cytometry for reconstitution and differentiation (Figure 4c). The
cultures seeded with CD44+/CD24-/ESA+  enriched cells
expand back into cultures nearly identical to the parental cell
line and unsorted cultures that were seeded in parallel (Figure
4c). For the SUM149 cell line, this reconstitution and differen-
tiation represents a change from nearly 100% CD24- to 5.7%
CD24-, whereas for the SUM159 cell line reconstitution and
differentiation represents a change from nearly 100% ESA+ to
1.9% ESA+. In contrast, cultures derived from CD44+/
CD24+/ESA+ cells from either cell line remained 98% CD44+/
CD24+/ESA+.
We next examined the phenotype of the cell colonies that
expanded after sorting and replating. Consistent with the fluo-
rescence-activated cell sorting data (Figure 4c), CD44+/
CD24-/ESA+ enriched cells formed heterogeneous mixed col-
onies that best recapitulated the morphological phenotype of
the parental cell line (Figure 4d). In contrast, colonies derived
Figure 4
CD44+/CD24-/ESA+ cells are enriched for self-renewal activity in vitro CD44+/CD24-/ESA+ cells are enriched for self-renewal activity in vitro. (a) Serial colony-forming units (CFUs) from 300 SUM159 sorted cells. Data 
are present as mean ± standard error of the mean for three separate experiments. Exhaustion of CFU is defined as the P3 colonies = P2 colonies. 
(b) Flow chart describing sorting scheme for reconstitution. (c) SUM149 or SUM159 sorted cells were expanded and the cellular outgrowths were 
reanalyzed by flow cytometry to assay reconstitution of the parental line. The parental line was run through the flow cytometer and expanded in par-
allel to control of the effects of fluorescence-activated cell sorting (top).(d) Representative phase-contrast brightfield images of unsorted SUM159 
or SUM149, and colonies that grew out from CD44+/CD24+/ESA+, CD44+/CD24+/ESA-, CD44+/CD24-/ESA+, or CD44+/CD24-/ESA- sorted 
cells. ESA, epithelial-specific antigen.Breast Cancer Research    Vol 10 No 2    Fillmore and Kuperwasser 
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from CD44+/CD24+/ESA+ cells exhibited a luminal type phe-
notype, whereas CD44+/CD24-/ESA-  colonies exhibited a
basal type phenotype regardless of the cell line from which the
cells were sorted from. These data further support the finding
(Figure 1) that a basal or luminal cellular phenotype is consist-
ent with CD44+/CD24-/ESA- or CD44+/CD24+/ESA+ cells. It
is worth noting that CD44+/CD24-/ESA- basal cells from the
SUM149 line have a capacity to generate CD44+/CD24+/
ESA+ cells, but this differentiation is significantly less efficient
than that of the stem-like cells.
The operational definition of stem cell activity is the ability to
self-renew and reconstitute a phenotypically diverse popula-
tion of cells. Because cancer cell lines are generally less het-
erogeneous than freshly isolated primary tumor cells and have
the ability to grow indefinitely, in principle this property may not
be maintained in established cell lines. However, these data
collectively demonstrate that human breast cancer cell lines
maintain a cellular hierarchy, such that a small fraction of cells
enriched in the CD44+CD24-ESA+ subpopulation can self-
renew (as indicated by increasing serial CFUs) and can recon-
stitute the differentiation spectrum of the parental cell line.
Sphere formation mimics tissue regeneration and 
correlates with tumorigenicity
Suspension sphere cultures have been used to enrich for and
characterize stem/progenitor cells from primary breast and
glioblastomic tissues [24,27,28]. This process is presumed to
simulate the events of tissue regeneration and maintenance
from cells that survive suspension conditions. In this process,
an initial phase of symmetric expansion of the seeding stem
cells precedes a phase of asymmetric division, which gives
rise to the differentiated progeny that comprise the sphere
bulk. To evaluate whether tumorsphere formation indeed mir-
rors tissue regeneration in our breast cancer cell lines, we
assayed the percentages of CD44+/CD24-/ESA+  cells in
maturing tumorspheres. We reasoned that if each sphere is
seeded and maintained by a small population of CD44+/
CD24-/ESA+ stem cells, then smaller spheres will contain an
over-representation of CD44+/CD24-/ESA+ compared with
large spheres or nearly confluent adherent cultures, both of
which will contain more differentiated progeny cells.
We used cell strainers to separate spheres larger than 100
μm from smaller spheres (Figure 5a). Collected tumorspheres
were dissociated into single cell suspension and analyzed by
flow cytometry for the percentage of CD44+/CD24-/ESA+
cells. SUM159 tumorspheres less than 100 μm contained six-
fold more CD44+/CD24-/ESA+ cells, whereas larger tumor-
spheres contained a similar percentage of CD44+/CD24-/
ESA+ cells to that of a nearly confluent adherent culture (Fig-
ure 5b). Comparable fold increases were also observed for the
smaller SUM1315 and SUM149 tumorspheres compared
with matched adherent cultures (Additional file 4 [part A]).
Figure 5
Tumorsphere formation correlates with presence of CD44+/CD24-/ESA+ cells Tumorsphere formation correlates with presence of CD44+/CD24-/ESA+ cells. (a) Phase-contrast brightfield image of SUM159 tumorspheres at 
day 11 under a 10× objective. (b) Representative flow cytometry profiles of SUM159 cells grown in adherent or nonadherent cultures. Nonadherent 
tumorspheres were filtered through cell strainers to separate spheres smaller than 100 μm from spheres larger than 100 μm. Percentage indicated 
in epithelial-specific antigen (ESA) histograms represents the population of CD44+/CD24-/ESA+ cells. (c) For each cell line, 5,600 single cells/cm2 
were plated on super-low adherence plates and spheres visible by eye were counted every 3 days. (d) The absolute number of tumorspheres on day 
12 was divided by the corresponding crystal violet value (see Materials and methods) for each cell line to correct for the proliferation rate of the cell 
lines.Available online http://breast-cancer-research.com/content/10/2/R25
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Next, to evaluate whether tumorsphere formation is related to
the percentage of CD44+/CD24-/ESA+ cells, the number of
spheres formed by each cell line was quantified. The absolute
number of tumorspheres that develop increases over 12 days
(Figure 5c), suggesting that the proliferation rate of the cell line
contributes to the number of observable spheres. Because the
growth rate of suspension cultures is similar to that of matched
adherent cultures (Additional file 4 [part B]), and the prolifera-
tion rates among the cell lines vary (Additional file 4 [part C]),
tumorsphere formation was normalized to the proliferation rate
of each cell line (Figure 5d). In doing so, it is clear that tumor-
sphere formation correlates with the percentage of CD44+/
CD24-/ESA+ cells in the cell line (Figures 5d and 2d), and thus
also correlates with tumorigenicity.
CD44+/CD24-/ESA+ cells cycle more slowly and are 
resistant to chemotherapies
Slower cell cycle kinetics and the ability to retain DNA label
are characteristics of normal tissue stem cells that have been
assayed by [3H]deoxythymidine or BrdU incorporation
[29,30]. To determine whether cancer stem-like cells in cell
lines share this attribute, asynchronous SUM159 and
MDA.MB.231 cells were cultured with BrdU for 10 days,
allowing incorporation of BrdU label into DNA of all cells
(Additional file 5 [part A]). Cells were then replated at low den-
sities and chased with non-BrdU containing media to examine
label retention at 4, 6, or 8 days after chase. After 6 days of
chase, 7% of cells stained for partial BrdU label retention,
seen as speckles in the nucleus, indicating that at least one
round of DNA replication and division had taken place (Figure
6a,b). In contrast, only 0.9% of cells retained complete BrdU
labeling, indicating a failure to divide during the chase period
(Figure 6a,b). By flow cytometry, 90% of the CD44+/CD24-/
ESA+ cells contain BrdU label 6 days after chase, whereas
again only 7% of the total population is BrdU+ using the same
gate (Figure 6c and data not shown). Furthermore, cells con-
taining the highest 1% of BrdU label, corresponding to com-
plete BrdU label retention and therefore a lack of division
during the chase period, are comprised of only 30% CD44+/
CD24-/ESA+ cells (Additional file 5 [part B]). Cultures were
immunostained for BrdU and the proliferation marker Ki67 at 6
days after chase to examine the proliferation rate of the cells.
As expected, nearly all of the cells in the cultures stained
positive for Ki67, indicating that most cells are in S-phase.
Figure 6
CD44+/CD24-/ESA+ cells retain BrdU label CD44+/CD24-/ESA+ cells retain BrdU label. (a) SUM159 were continuously treated with 5-bromo-2-deoxyuridine (BrdU) for 10 days. Cells that 
stain for BrdU label 6 days after chase exhibit either a solid or speckled pattern of label retention: BrdU (green) or DAPI (4',6 diamidino-2-phenylin-
dole; blue). (b) SUM159 and MDA.MB.231 cells were pulse-chased with BrdU. The percentage of cells with either solid or speckled BrdU staining 
were counted at the indicated time points. Data are presented as the mean ± standard error of the mean for at least three separate 10× fields of two 
separate experiments. (c) Proliferating cultures of SUM159 cells were pulse-chased and analyzed by flow cytometry for CD44+/CD24-/ESA+ and 
the presence of BrdU. Note that about 90% of CD44+/CD24-/ESA+ SUM159 cells retain BrdU label at 6 days after chase. (d) Immunoflourescence 
of BrdU and Ki67 in cells that were BrdU pulse-chased. (i) Co-localization of BrdU (green) and Ki67 (red); note that of the adjacent nuclei that are 
both Ki67 positive, only one contains BrdU. ESA, epithelial-specific antigen.Breast Cancer Research    Vol 10 No 2    Fillmore and Kuperwasser 
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Interestingly, 80% of the BrdU+ cells also stained positive for
Ki67 (Figure 6d [indicated by i]), further supporting the notion
that BrdU label retention is not specific only for quiescent
cells. These results indicate that CD44+/CD24-/ESA+ cells do
cycle but at a slower rate than the bulk of the cell line.
Given that breast cancer cell lines contain cells that exhibit
properties of cancer stem-like cells, and cancer-initiating cells
in primary human leukemia and glioblastoma are resistant to
chemotherapy [31,32], we sought to determine whether cell
line-derived CD44+/CD24-/ESA+ cells would also preferen-
tially survive treatment with chemotherapeutic agents. To this
end, nonconfluent adherent cultures of SUM159, SUM1315,
and MDA.MB.231 cells were treated for 6 days with high dose
10 nmol/l paclitaxel (Taxol) or 1 mmol/l 5-FU (Additional file 6
[part A]). Of the surviving cells, CD44+/CD24-/ESA+ cells
were enriched 5-fold to 30-fold in chemotherapy-treated cul-
tures as compared with placebo-treated control cultures (Fig-
ure 7a). As expected for cell cycle inhibitory drugs, the cell line
with the highest proliferation rate, MDA.MB.231, exhibited the
greatest cytotoxicity (Additional files 4 [part C] and 6 [part B]),
but of the 1% surviving cells after Taxol or 5-FU treatment an
average of 30% or 35% were CD44+/CD24-/ESA+, respec-
tively (Figure 7a).
The observation that 90% of CD44+/CD24-/ESA+ cells retain
BrdU label in an untreated asynchronously diving culture sug-
gests that one mechanism by which these cells preferentially
survive cell cycle inhibitory agents could be that they divide
more slowly or remain quiescent compared with the bulk of the
line. To examine this possibility, BrdU-labeled cultures were
chased for 6 days with media containing 10 nmol/l Taxol or 1
mmol/l 5-FU. In contrast to cells chased with plain media,
nearly all of the cells with intact nuclei following chemotherapy
chase were BrdU+, yet 30% to 70% of these cells exhibited
the speckled pattern of BrdU staining, consistent with the
notion that they had undergone cell division. Hence, although
cells that survive chemotherapy do cycle more slowly, they
continue to replicate, which suggests that their resistance is
not due solely to quiescence (Figure 7b and Additional file 6
[part C]). Taken together, these data show that CD44+/CD24-
/ESA+ cells in breast cancer lines exhibit increased resistance
to chemotherapy, providing evidence for a mechanism of post-
treatment recurrence.
Discussion
Although the existence of tumor-initiating cells in solid human
tumors is widely accepted, it is unclear whether cancer-
derived cell lines contain similar cells. Primary carcinoma cells
are presumed to be the only representatives of actual human
cancers, because prolonged in vitro culturing is thought to
result in loss of crucial properties including hierarchal organi-
zation and heterogeneity found in tumors [7]. However, we
have found that established breast cancer cell lines posses a
small fraction of self-renewing tumorigenic cells with the
capacity to differentiate into phenotypically diverse progeny.
This observation suggests that cell lines are excellent models
in which to study cancer stem cells.
We found that CD44+/CD24-/ESA+ cells exhibit properties of
self-renewal in vitro, form tumors from very few cells, divide
slowly, and are selectively resistant to chemotherapy, all of
which are hallmarks of cancer stem cells. In light of recent
studies that suggest that presence of CD44+/CD24- cells
does not correlate with clinical outcome [33] or with distant
metastasis [17], we also found that cell lines with few CD44+/
CD24- cells were not necessarily less tumorigenic than cell
lines with very high numbers of CD44+/CD24- cells. However,
it is important to note that in luminal cell lines that are nearly
100% ESA+ (MCF7 and SUM225), sorting cells for the phe-
Figure 7
CD44+/CD24-/ESA+ cells preferentially survive chemotherapy CD44+/CD24-/ESA+ cells preferentially survive chemotherapy. (a) Quantification of viable CD44+/CD24-/ESA+ cells in various human breast can-
cer cell lines following a 6-day treatment with 10 nmol/l paclitaxol (Taxol) or 1 mm 5-fluorouracil (5-FU). Data are presented as the mean ± standard 
error of the mean for four separate experiments. (b) SUM159 cells were continuously treated with BrdU for 10 days and chased with media contain-
ing 10 nmol/l Taxol or 1 mmol/l 5-FU. On day 6 of the chase, cells were stained for 5-bromo-2-deoxyuridine (BrdU) and counted for the solid (com-
plete label retention) and speckled (partial label retention) staining. DMSO, dimethyl sulfoxide.Available online http://breast-cancer-research.com/content/10/2/R25
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notype CD44+/CD24- is sufficient to enrich for tumorigenic
cells. In contrast, in basal cell lines with high percentages of
CD44+/CD24-  cells (MDA.MB.231, SUM159, and
SUM1315), sorting for ESA+ cells is sufficient to enrich for
breast cancer-initiating cells. Finally, in cell lines that exhibit
two distinct CD44/CD24 populations (for example, SUM149),
all three markers are required to enrich correctly for tumor-ini-
tiating stem-like cells.
Tumor progression is thought to result from the genetic insta-
bility within cancer cells that selects for clonal expansion and
evolution of more aggressive tumor behaviors over time.
However, despite continual genetic and phenotypic drift,
breast cancers do not radically change their phenotype, even
after many years or various therapeutic regimens. Likewise,
cancer cell lines do not radically change their phenotype over
many passages [9]. Although it is indeed possible to select
clonogenic variants within a cell line that exhibit different
genetic and biological properties from the parental population,
it is widely recognized that single cell cloning is extremely inef-
ficient, yielding few clones with the capacity to expand and
propagate indefinitely. Moreover, single cell clones derived
from the same cancer cell line are not equally tumorigenic or
metastatic [34-36]. This observation supports the notion that
not every cell within a cell line can self-renew or is equally tum-
origenic, further illustrating that cell lines possess a functional
hierarchy and heterogeneity akin to primary tumors.
During the course of characterizing the hierarchal dynamics of
cells in culture, we observed that the percentage of CD44+/
CD24-/ESA+ cells within a line varied depending on various
conditions. For example, cell density, the presence or absence
of growth factors, and even the frequency of passaging influ-
enced the percentage of CD44+/CD24-/ESA+ cells detected
in a cell line. These observations suggest that the dynamic
nature of cell lines is regulated by their immediate
microenvironment.
Conclusion
Although the existence of tumor-initiating cells in solid human
tumors is widely accepted, it is unclear whether cancer
derived cell lines contain similar cells. Here, we show that
human breast cancer cell lines exhibit a cellular hierarchy that
is characteristic of primary breast tumors, in which a small
population of cells with the CD44+CD24-ESA+ phenotype
enriches for tumor-initiating cells that self-renew in vitro and
give rise to phenotypically diverse progeny. The fact that a
small population of these breast cancer stem-like cells sur-
vives chemotherapy is consistent with the notion that the sur-
viving tumorigenic cells are responsible for the 40%
recurrence rate of invasive breast cancer. Therefore, it will be
of great interest to determine whether CD44+/CD24-/ESA+
cells are directly targeted by alternative therapies such as
monoclonal antibody treatment or novel small molecule inhibi-
tors. Based on our results, using breast cancer cell lines to
target CD44+/CD24-/ESA+ cells for drug discovery offers a
highly promising, reproducible, and cost-effective means to
identify therapies that prevent self-renewal or force depletion
of tumorigenic breast cancer stem-like cells.
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